HAND1 and metabolic dysfunction-associated steatotic liver disease: In 2022, Panera N. et al., through in vitro and in vivo approaches, demonstrated the potential therapeutic effect of Vit E alone or in combination with HXT to protect against NAFLD-related hepatic fibrosis, suggesting that supplementation with Vit E in combination with HXT can represent a potential therapeutic approach to improve NAFLD-related liver fibrosis, inducing a reduction of the disease progression risk [45].